肿瘤
词汇介绍
拓展阅读
解析
Crizotinib
释 义 n. 克唑替尼(药物名称)
例 句 Crizotinib activity in patients with ROS1-translocated tumours was confirmed. 克唑替尼在ROS1易位肿瘤患者中的活性得到证实。
概述
Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer复制标题
吉美替尼与克唑替尼治疗ALK阳性非小细胞肺癌的比较
发表时间:2018-11-22
影响因子:70.7
作者: D.R. Camidge
期刊:N. Engl. J. Med.
A total of 275 patients underwent randomization; 137 were assigned to brigatinib and 138 to crizotinib. At the first interim analysis (99 events), the median follow-up was 11.0 months in the brigatinib group and 9.3 months in the crizotinib group. The rate of progression-free survival was higher with brigatinib than with crizotinib (estimated 12-month progression-free survival, 67% [95% confidence interval {CI}, 56 to 75] vs. 43% [95% CI, 32 to 53]; hazard ratio for disease progression or death, 0.49 [95% CI, 0.33 to 0.74]; P<0.001 by the log-rank test). The confirmed objective response rate was 71% (95% CI, 62 to 78) with brigatinib and 60% (95% CI, 51 to 68) with crizotinib; the confirmed rate of intracranial response among patients with measurable lesions was 78% (95% CI, 52 to 94) and 29% (95% CI, 11 to 52), respectively. No new safety concerns were noted. Among patients with ALK-positive NSCLC who had not previously received an ALK inhibitor, progression-free survival was significantly longer among patients who received brigatinib than among those who received crizotinib. (Funded by Ariad Pharmaceuticals; ALTA-1L ClinicalTrials.gov number, NCT02737501.).
译文